BRPI0914802A2 - Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo. - Google Patents

Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.

Info

Publication number: BRPI0914802A2
Authority: BR; Brazil
Prior art keywords: prodrug; compound; drug
Prior art date: 2008-06-19

Application number

BRPI0914802-7A

Other languages

English (en)

Inventor

Takanobu Kuroita

Yasuhiro Imaeda

Kouichi Iwanaga

Naohiro Taya

Hidekazu Tokuhara

Yoshiyuki Fukase

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-19

Filing date

2009-06-17

Publication date

2015-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914802(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-17 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2015-08-11 Publication of BRPI0914802A2 publication Critical patent/BRPI0914802A2/pt

2020-10-27 Publication of BRPI0914802B1 publication Critical patent/BRPI0914802B1/pt

2021-05-25 Publication of BRPI0914802B8 publication Critical patent/BRPI0914802B8/pt

Links

150000001875 compounds Chemical class 0.000 title 2
229940002612 prodrug Drugs 0.000 title 2
239000000651 prodrug Substances 0.000 title 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Enzymes And Modification Thereof (AREA)
Hydrogenated Pyridines (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0914802A 2008-06-19 2009-06-17 composto heterocíclico, e, medicamento BRPI0914802B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2008-161049		2008-06-19
JP2008161049		2008-06-19
JP2009004882		2009-01-13
JP2009-004882		2009-01-13
PCT/JP2009/061438 WO2009154300A2 (en)	2008-06-19	2009-06-17	Heterocyclic compound and use thereof

Publications (3)

Publication Number	Publication Date
BRPI0914802A2 true BRPI0914802A2 (pt)	2015-08-11
BRPI0914802B1 BRPI0914802B1 (pt)	2020-10-27
BRPI0914802B8 BRPI0914802B8 (pt)	2021-05-25

Family

ID=41282529

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914802A BRPI0914802B8 (pt)	2008-06-19	2009-06-17	composto heterocíclico, e, medicamento

Country Status (38)

Country	Link
US (5)	US8664380B2 (pt)
EP (1)	EP2297114B1 (pt)
JP (3)	JP4800445B2 (pt)
KR (2)	KR101207830B1 (pt)
CN (2)	CN103373985B (pt)
AR (1)	AR072166A1 (pt)
AU (1)	AU2009261153B2 (pt)
BR (1)	BRPI0914802B8 (pt)
CA (1)	CA2728476C (pt)
CL (1)	CL2010001361A1 (pt)
CO (1)	CO6300862A2 (pt)
CR (2)	CR20110001A (pt)
CY (1)	CY1120995T1 (pt)
DK (1)	DK2297114T3 (pt)
DO (2)	DOP2010000381A (pt)
EA (2)	EA201301040A1 (pt)
EC (1)	ECSP11010770A (pt)
ES (1)	ES2676289T3 (pt)
GE (2)	GEP20135957B (pt)
HR (1)	HRP20181370T1 (pt)
HU (1)	HUE039416T2 (pt)
IL (1)	IL209282A (pt)
JO (1)	JO3465B1 (pt)
LT (1)	LT2297114T (pt)
MA (1)	MA32483B1 (pt)
MX (2)	MX2010013602A (pt)
MY (1)	MY160771A (pt)
NZ (2)	NZ600238A (pt)
PE (2)	PE20110067A1 (pt)
PL (1)	PL2297114T3 (pt)
PT (1)	PT2297114T (pt)
RS (1)	RS57591B1 (pt)
SG (1)	SG188117A1 (pt)
SI (1)	SI2297114T1 (pt)
TW (2)	TWI472523B (pt)
UY (1)	UY31907A (pt)
WO (1)	WO2009154300A2 (pt)
ZA (1)	ZA201009073B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009051112A1 (ja)	2007-10-15	2009-04-23	Takeda Pharmaceutical Company Limited	アミド化合物およびその用途
JP5484069B2 (ja)	2007-12-19	2014-05-07	大日本住友製薬株式会社	二環性へテロ環誘導体
NZ600238A (en)	2008-06-19	2014-04-30	Takeda Pharmaceutical	Heterocyclic compound and use thereof
US9090601B2 (en)	2009-01-30	2015-07-28	Millennium Pharmaceuticals, Inc.	Thiazole derivatives
KR20120109292A (ko)	2009-06-24	2012-10-08	다이닛본 스미토모 세이야꾸 가부시끼가이샤	Ｎ-치환-시클릭 아미노 유도체
US20110152243A1 (en) *	2009-12-23	2011-06-23	Abbott Laboratories	Novel thienopyrrole compounds
US9018374B2 (en)	2010-06-16	2015-04-28	Takeda Pharmaceutical Company Limited	Crystal of amide compound
EP2638035B1 (en) *	2010-11-09	2014-12-17	F.Hoffmann-La Roche Ag	Triazole derivatives as ligands for Gaba receptors
US8742097B2 (en) *	2010-11-09	2014-06-03	Hoffmann-La Roche Inc.	Triazole compounds I
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
US9382192B2 (en) *	2012-02-14	2016-07-05	Dow Global Technologies Llc	Nonionic surfactant compositions
CA2864068A1 (en) *	2012-02-15	2013-08-22	Takeda Pharmaceutical Company Limited	Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
US9475797B2 (en) *	2012-06-26	2016-10-25	Saniona A/S	Phenyl triazole derivative and its use for modulating the GABAA receptor complex
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
EP3130581A4 (en)	2014-04-10	2017-11-22	Takeda Pharmaceutical Company Limited	Method for producing heterocyclic compound
CA2947741A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9999626B2 (en)	2014-06-18	2018-06-19	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of active agents
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US10758525B2 (en)	2015-01-22	2020-09-01	MyoKardia, Inc.	4-methylsulfonyl-substituted piperidine urea compounds
ES2827796T3 (es)	2016-06-03	2021-05-24	Thetis Pharmaceuticals Llc	Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
CN108727249A (zh) *	2018-07-07	2018-11-02	台州学院	3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
CN114127061A (zh)	2019-07-16	2022-03-01	迈奥卡迪亚公司	(r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL102183A (en)	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
RU2168510C2 (ru)	1991-07-31	2001-06-10	Такеда Кемикал Индастриз, Лтд.	Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en)	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
FI974437A7 (fi)	1995-06-06	1997-12-05	Pfizer	Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
UA58494C2 (uk)	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
IL120724A0 (en)	1995-09-01	1997-08-14	Lilly Co Eli	Indolyl neuropeptide Y receptor antagonists
TWI227240B (en)	2000-06-06	2005-02-01	Pfizer	2-aminocarbonyl-9H-purine derivatives
WO2002100833A1 (en)	2001-06-12	2002-12-19	Sumitomo Pharmaceuticals Company, Limited	Rho KINASE INHIBITORS
US20030078278A1 (en)	2001-06-26	2003-04-24	Pfizer Inc.	Spiropiperidine compounds as ligands for ORL-1 receptor
WO2003037274A2 (en)	2001-11-01	2003-05-08	Icagen, Inc.	Pyrazole-amides and-sulfonamides
PL370989A1 (en)	2001-12-21	2005-06-13	Novo Nordisk A/S	Amide derivatives as gk activators
AU2003249597B2 (en)	2002-03-08	2007-06-28	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
WO2004037171A2 (en)	2002-10-18	2004-05-06	Merck & Co., Inc.	Mitotic kinesin inhibitors
US20040204455A1 (en)	2003-04-10	2004-10-14	Cody Wayne Livingston	Piperidine derivative rennin inhibitors
CA2527033A1 (en)	2003-06-18	2004-12-23	Astrazeneca Ab	2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
EP1664026B1 (en)	2003-08-15	2009-01-21	Merck & Co., Inc.	Mitotic kinesin inhibitors
JP2007502773A (ja)	2003-08-15	2007-02-15	メルク　エンド　カムパニー　インコーポレーテッド	有糸分裂キネシン阻害薬
TW200900399A (en)	2003-10-01	2009-01-01	Speedel Experimenta Ag	Organic compounds
EP1685102A4 (en)	2003-11-12	2008-08-20	Lg Life Sciences Ltd	melanocortin
AR053406A1 (es)	2004-07-09	2007-05-09	Speedel Experimenta Ag	Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
AU2005273986A1 (en) *	2004-08-10	2006-02-23	Incyte Corporation	Amido compounds and their use as pharmaceuticals
BRPI0516132A (pt)	2004-10-07	2007-12-04	Vitae Pharmaceuticals Inc	compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
CA2587853A1 (en)	2004-11-23	2006-06-01	Wyeth	Gonadotropin releasing hormone receptor antagonists
GB0428526D0 (en)	2004-12-30	2005-02-09	Novartis Ag	Organic compounds
JP2008533144A (ja)	2005-03-16	2008-08-21	メルクエンドカムパニーインコーポレーテッド	有糸分裂キネシン阻害剤
GB0511063D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0514203D0 (en)	2005-07-11	2005-08-17	Novartis Ag	Organic compounds
CA2621181C (en) *	2005-08-30	2011-04-19	Asahi Kasei Pharma Corporation	5-isoquinolinesulfonamide compounds
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US7618982B2 (en)	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
BRPI0620736A2 (pt)	2005-12-30	2011-12-20	Novartis Ag	compostos orgánicos
TW200804359A (en)	2006-01-19	2008-01-16	Speedel Experimenta Ag	Substituted 4-phenylpiperidines
EP1984355A2 (en)	2006-02-16	2008-10-29	Takeda Pharmaceutical Company Limited	Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
WO2007111227A1 (ja)	2006-03-24	2007-10-04	Astellas Pharma Inc.	アシルアミノピペリジン化合物
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
WO2008009954A1 (en)	2006-07-21	2008-01-24	Astex Therapeutics Limited	Medical use of cyclin dependent kinases inhibitors
WO2008016666A2 (en) *	2006-08-02	2008-02-07	Cytokinetics, Incorporated	Certain chemical entities, compositions, and methods
EP2119702A4 (en) *	2007-01-31	2010-12-08	Dainippon Sumitomo Pharma Co	amide derivative
JP4837701B2 (ja)	2007-04-20	2011-12-14	田辺三菱製薬株式会社	医薬組成物
JP2010163361A (ja) *	2007-04-27	2010-07-29	Dainippon Sumitomo Pharma Co Ltd	キノリン誘導体
TW200904433A (en)	2007-04-27	2009-02-01	Takeda Pharmaceutical	Substituted imidazole compound and use thereof
JP2010189275A (ja)	2007-06-14	2010-09-02	Dainippon Sumitomo Pharma Co Ltd	ナフタレン誘導体
TWI452044B (zh) *	2007-06-15	2014-09-11	Mitsubishi Tanabe Pharma Corp	嗎啉衍生物
WO2009001915A1 (ja)	2007-06-28	2008-12-31	Takeda Pharmaceutical Company Limited	置換イミダゾール化合物およびその用途
JP2010208947A (ja) *	2007-06-29	2010-09-24	Dainippon Sumitomo Pharma Co Ltd	キノロン誘導体
JP2010229034A (ja) *	2007-07-26	2010-10-14	Dainippon Sumitomo Pharma Co Ltd	二環性ピロール誘導体
WO2009051112A1 (ja)	2007-10-15	2009-04-23	Takeda Pharmaceutical Company Limited	アミド化合物およびその用途
JP2011037712A (ja)	2007-12-08	2011-02-24	Dainippon Sumitomo Pharma Co Ltd	４−アリールフェニル誘導体
JP5484069B2 (ja)	2007-12-19	2014-05-07	大日本住友製薬株式会社	二環性へテロ環誘導体
AR070454A1 (es)	2008-02-27	2010-04-07	Nycomed Gmbh	Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
US20110098288A1 (en)	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) *	2008-06-11	2009-12-24	Daiichi Sankyo Co Ltd	イミダゾチアゾール誘導体
NZ600238A (en) *	2008-06-19	2014-04-30	Takeda Pharmaceutical	Heterocyclic compound and use thereof
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬

2009
- 2009-06-17 NZ NZ600238A patent/NZ600238A/en not_active IP Right Cessation
- 2009-06-17 WO PCT/JP2009/061438 patent/WO2009154300A2/en not_active Ceased
- 2009-06-17 HR HRP20181370TT patent/HRP20181370T1/hr unknown
- 2009-06-17 MY MYPI2010005939A patent/MY160771A/en unknown
- 2009-06-17 TW TW101121074A patent/TWI472523B/zh not_active IP Right Cessation
- 2009-06-17 MX MX2010013602A patent/MX2010013602A/es active IP Right Grant
- 2009-06-17 JP JP2010549957A patent/JP4800445B2/ja not_active Expired - Fee Related
- 2009-06-17 EA EA201301040A patent/EA201301040A1/ru unknown
- 2009-06-17 US US12/457,646 patent/US8664380B2/en not_active Expired - Fee Related
- 2009-06-17 GE GEAP200912066A patent/GEP20135957B/en unknown
- 2009-06-17 JO JOP/2009/0216A patent/JO3465B1/ar active
- 2009-06-17 EA EA201170051A patent/EA019755B1/ru not_active IP Right Cessation
- 2009-06-17 SG SG2013008842A patent/SG188117A1/en unknown
- 2009-06-17 CA CA2728476A patent/CA2728476C/en active Active
- 2009-06-17 AR ARP090102193A patent/AR072166A1/es active IP Right Grant
- 2009-06-17 UY UY0001031907A patent/UY31907A/es not_active Application Discontinuation
- 2009-06-17 PE PE2010001164A patent/PE20110067A1/es active IP Right Grant
- 2009-06-17 AU AU2009261153A patent/AU2009261153B2/en not_active Ceased
- 2009-06-17 PT PT97667489T patent/PT2297114T/pt unknown
- 2009-06-17 TW TW098120213A patent/TWI378096B/zh active
- 2009-06-17 LT LTEP09766748.9T patent/LT2297114T/lt unknown
- 2009-06-17 HU HUE09766748A patent/HUE039416T2/hu unknown
- 2009-06-17 CN CN201310292451.2A patent/CN103373985B/zh not_active Expired - Fee Related
- 2009-06-17 EP EP09766748.9A patent/EP2297114B1/en active Active
- 2009-06-17 ES ES09766748.9T patent/ES2676289T3/es active Active
- 2009-06-17 CN CN200980132372.7A patent/CN102123990B/zh active Active
- 2009-06-17 KR KR1020117001002A patent/KR101207830B1/ko active Active
- 2009-06-17 SI SI200931871T patent/SI2297114T1/sl unknown
- 2009-06-17 PE PE2013001363A patent/PE20140858A1/es not_active Application Discontinuation
- 2009-06-17 RS RS20180895A patent/RS57591B1/sr unknown
- 2009-06-17 US US12/999,428 patent/US8466282B2/en not_active Expired - Fee Related
- 2009-06-17 KR KR1020127014751A patent/KR101578264B1/ko not_active Expired - Fee Related
- 2009-06-17 BR BRPI0914802A patent/BRPI0914802B8/pt not_active IP Right Cessation
- 2009-06-17 GE GEAP200913059A patent/GEP20166443B/en unknown
- 2009-06-17 PL PL09766748T patent/PL2297114T3/pl unknown
- 2009-06-17 DK DK09766748.9T patent/DK2297114T3/en active
- 2009-06-17 NZ NZ589825A patent/NZ589825A/xx not_active IP Right Cessation
2010
- 2010-11-11 IL IL209282A patent/IL209282A/en active IP Right Grant
- 2010-12-06 CL CL2010001361A patent/CL2010001361A1/es unknown
- 2010-12-08 DO DO2010000381A patent/DOP2010000381A/es unknown
- 2010-12-09 MX MX2012014481A patent/MX338557B/es unknown
- 2010-12-17 ZA ZA2010/09073A patent/ZA201009073B/en unknown
2011
- 2011-01-10 CR CR20110001A patent/CR20110001A/es unknown
- 2011-01-14 MA MA33527A patent/MA32483B1/fr unknown
- 2011-01-19 EC EC2011010770A patent/ECSP11010770A/es unknown
- 2011-01-19 CO CO11005108A patent/CO6300862A2/es active IP Right Grant
- 2011-04-08 JP JP2011086570A patent/JP5592831B2/ja not_active Expired - Fee Related
2012
- 2012-04-13 US US13/446,408 patent/US9045436B2/en active Active
2013
- 2013-05-31 DO DO2013000123A patent/DOP2013000123A/es unknown
- 2013-07-24 CR CR20130360A patent/CR20130360A/es unknown
- 2013-12-27 JP JP2013273076A patent/JP5918746B2/ja not_active Expired - Fee Related
2015
- 2015-03-23 US US14/665,237 patent/US9221836B2/en not_active Expired - Fee Related
- 2015-10-28 US US14/925,259 patent/US20160046601A1/en not_active Abandoned
2018
- 2018-09-04 CY CY181100913T patent/CY1120995T1/el unknown

Also Published As

Publication number	Publication date
EP2297114A2 (en)	2011-03-23
US20110178057A1 (en)	2011-07-21
PE20140858A1 (es)	2014-08-04
US9221836B2 (en)	2015-12-29
US20100137587A1 (en)	2010-06-03
AU2009261153B2 (en)	2014-05-22
WO2009154300A3 (en)	2010-06-03
US8466282B2 (en)	2013-06-18
AU2009261153A1 (en)	2009-12-23
BRPI0914802B8 (pt)	2021-05-25
UY31907A (es)	2010-01-29
RS57591B1 (sr)	2018-11-30
MY160771A (en)	2017-03-15
CO6300862A2 (es)	2011-07-21
NZ600238A (en)	2014-04-30
BRPI0914802B1 (pt)	2020-10-27
ES2676289T3 (es)	2018-07-18
IL209282A0 (en)	2011-01-31
DOP2013000123A (es)	2013-11-15
TW201240987A (en)	2012-10-16
SG188117A1 (en)	2013-03-28
SI2297114T1 (sl)	2018-10-30
KR101578264B1 (ko)	2015-12-16
US20120264733A1 (en)	2012-10-18
US20160046601A1 (en)	2016-02-18
LT2297114T (lt)	2018-08-10
ZA201009073B (en)	2012-03-28
EA019755B1 (ru)	2014-06-30
ECSP11010770A (es)	2011-02-28
EP2297114B1 (en)	2018-06-06
JP5592831B2 (ja)	2014-09-17
MX2010013602A (es)	2011-03-15
TWI378096B (en)	2012-12-01
NZ589825A (en)	2012-11-30
CN102123990B (zh)	2014-07-09
TW201002685A (en)	2010-01-16
MX338557B (es)	2016-04-21
JP2011524853A (ja)	2011-09-08
GEP20166443B (en)	2016-03-10
CA2728476A1 (en)	2009-12-23
EA201301040A1 (ru)	2014-01-30
CN103373985B (zh)	2015-10-28
JP5918746B2 (ja)	2016-05-18
CR20110001A (es)	2013-03-15
PL2297114T3 (pl)	2018-10-31
HUE039416T2 (hu)	2018-12-28
JP2011157391A (ja)	2011-08-18
CA2728476C (en)	2017-03-21
CL2010001361A1 (es)	2011-07-29
KR20110019428A (ko)	2011-02-25
EA201170051A1 (ru)	2011-08-30
TWI472523B (zh)	2015-02-11
AR072166A1 (es)	2010-08-11
IL209282A (en)	2015-07-30
JP4800445B2 (ja)	2011-10-26
US9045436B2 (en)	2015-06-02
JP2014094950A (ja)	2014-05-22
PE20110067A1 (es)	2011-02-18
CR20130360A (es)	2013-09-03
US20150191486A1 (en)	2015-07-09
GEP20135957B (en)	2013-11-11
CY1120995T1 (el)	2019-12-11
MA32483B1 (fr)	2011-07-03
HRP20181370T1 (hr)	2018-10-19
WO2009154300A2 (en)	2009-12-23
KR20120084778A (ko)	2012-07-30
DOP2010000381A (es)	2010-12-31
DK2297114T3 (en)	2018-07-09
KR101207830B1 (ko)	2012-12-04
CN102123990A (zh)	2011-07-13
PT2297114T (pt)	2018-07-26
CN103373985A (zh)	2013-10-30
JO3465B1 (ar)	2020-07-05
US8664380B2 (en)	2014-03-04

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-19	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-05-14	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-03-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-09-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-27	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-08-24	B25A	Requested transfer of rights approved	Owner name: SCOHIA PHARMA, INC. (JP)
2024-04-09	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2024-07-30	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2779 DE 09-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0914802A2 (pt)	2015-08-11	Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0907563A2 (pt)	2015-08-04	Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
CL2007002783S1 (es)	2008-07-04	Inhalador multidosis.
BRPI0815773A2 (pt)	2019-09-24	composto, e, medicamento.
NL2000627A1 (nl)	2007-11-12	Cycloalkylaminoderivaten.
BRPI0813235A2 (pt)	2014-12-23	Combinação anti-helmíntica.
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
FR2909442B1 (fr)	2013-12-27	Telemetre.
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0816970A2 (pt)	2015-03-24	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0814736A2 (pt)	2017-06-06	inalador.
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
ITMI20071002A1 (it)	2008-11-18	Manufatto per edilizia.
BRPI0807078A2 (pt)	2014-04-08	Composto, e, formulação farmacêutica
BRPI1016190A2 (pt)	2017-03-28	compostos farmacêuticos.